- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07945795
RDN for CKD and Uncontrolled Hypertension Trial
Effect and Safety of Renal Denervation in Uncontrolled Hypertension and Chronic Kidney Disease: A Randomized, Sham-control, Blinded, Clinical Trial
Prospective, Multi-Center, Randomized, Parallel-Controlled, Uptake clinical trial to evaluate the efficacy and safety of renal denervation in patients with uncontrolled hypertension and chronic kidney disease.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
This Prospective, Multi-Center, Randomized, parallel-controlled uptake clinical trial aims to evaluate the efficacy and safety for renal denervation in patients with uncontrolled hypertension and chronic kidney disease, and to provide clinical evidence supporting the expansion of indications.
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiekontakt
- Navn: Luyun Fan
- Telefonnummer: +86-13522601484
- E-mail: katevan@163.com
Undersøgelse Kontakt Backup
- Navn: Jingjing Zhou
- Telefonnummer: +86-18742568090
- E-mail: zhoujjrf0901@163.com
Studiesteder
-
-
-
Beijing, Kina, 101118
- Rekruttering
- Beijing Anzhen Hospital
-
Kontakt:
- Jun Cai
- Telefonnummer: +86-13810615602
- E-mail: caijun7879@126.com
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Male or female, aged 18 to 65 years, inclusive, at the time of consent;
- Hypertensive subjects who have been taking 2 types of standardized antihypertensive drugs continuously and stably for at least 4 weeks, with office systolic blood pressure still ≥150 mmHg and <180 mmHg, and 24-hour ambulatory mean systolic blood pressure (24h SBP) ≥135 mmHg and <170 mmHg; or who have been taking ≥3 types of standardized antihypertensive drugs continuously and stably for at least 4 weeks, with office systolic blood pressure ≥140 mmHg and <180 mmHg, and 24h SBP ≥130 mmHg and <170 mmHg;
- Estimated glomerular filtration rate (eGFR) ≥20 mL/min/1.73m² and <60 mL/min/1.73m²;
- The presence or absence of accessory renal arteries is acceptable;
- The subject or his/her legal representative fully understands the content of the informed consent form for this trial and voluntarily signs the written informed consent form.
Exclusion Criteria:
- Pregnant or breastfeeding, or planning pregnancy during the study.
- Renal artery anatomy unsuitable for ablation (e.g., ≥50% stenosis, renal artery aneurysm, malformation, renal artery diameter <3 mm, or treatable segment length <20 mm).
- Subjects with a solitary kidney, prior renal transplantation, or requiring dialysis.
- Prior renal artery intervention or prior renal denervation.
- Other secondary hypertension not related to kidney disease (such as primary aldosteronism, pheochromocytoma/paraganglioma, Cushing's syndrome, thyroid disease, aortic coarctation, monogenic hypertension, renovascular hypertension, etc.).
- Allergic to contrast agents.
- Major surgery or trauma within 1 month before enrollment; acute coronary syndrome within 6 months; or planned surgery or cardiovascular interventional therapy within the next 6 months.
- Orthostatic hypotension.
- Type 1 diabetes mellitus.
- Primary pulmonary arterial hypertension.
- History of bleeding diathesis and haematological disorders or coagulopathy
- History of thromboembolic event within 6 months.
- History of stroke or transient ischemic attack (TIA) within 6 months.
- Severe peripheral arterial disease or unstable abdominal aortic aneurysm.
- Severe valvular heart disease or anticipated need for surgical valve replacement during the study period.
- NYHA Class III/IV heart failure at screening or hospitalization for exacerbation of chronic heart failure within the past six months.
- History of ventricular fibrillation, polymorphic ventricular tachycardia within six months, or prior implantation of an implantable cardioverter-defibrillator (ICD) or pacemaker.
- Acute kidney injury (AKI) within 4 weeks before enrollment or acute kidney disease ,AKI: ≥50% increase in serum creatinine within 7 days, or absolute increase ≥0.3 mg/dL (≥26.5 μmol/L) within 48 hours, or oliguria (<0.5 mL·kg-¹·h-¹ for ≥6 hours).
- Severe hepatic dysfunction.
- Concomitant severe diseases that may interfere with study participation or affect survival, such as malignancy or AIDS.
- Known drug or alcohol dependence, difficulty understanding the study protocol, inability or unwillingness to comply with follow-up requirements.
- Current or planned participation in other clinical trials of drugs or medical devices (post-marketing registry studies permitted).
- Acute or severe systemic infection.
- Other conditions deemed unsuitable for participation by the investigator.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Enkelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Renal Denervation (RDN)
Participants receive percutaneous renal sympathetic denervation under digital subtraction angiography (DSA) guidance using a ultra-guiding radiofrequency denervation catheter. All participants receive a standardized antihypertensive regimen for ≥4 weeks before the procedure and thereafter per protocol. Follow-up visits occur at 7 days or before discharge, and at 1, 3, 6, 12 months. |
DSA-guided percutaneous renal sympathetic denervation using a RF renal denervation system
Andre navne:
|
|
Sham-komparator: Parallel control with sham operation
Participants undergo a sham procedure: femoral artery puncture and selective renal angiography under DSA guidance are performed. The RF generator is connected to a dummy load, and activation sounds are emitted, but no energy is delivered. Participants remain on the procedure table for at least 35 minutes before sheath removal. Background standardized antihypertensive therapy is provided for ≥4 weeks pre-procedure and continued per protocol. Follow-up visits occur at 7 days or before discharge, and at 1, 3, 6, and 12 months. |
Sham procedure including femoral artery puncture and selective renal angiography; the radiofrequency generator is connected to a dummy load and produces activation sounds, but no energy is delivered. Minimum table time before sheath removal is 35 minutes.
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Change from Baseline in 24-hour Ambulatory Systolic Blood Pressure at Month 6 (ABPM)
Tidsramme: Baseline to Month 6 post-procedure
|
24-hour mean systolic BP measured by validated ambulatory BP monitoring; change is Month 6 minus Baseline |
Baseline to Month 6 post-procedure
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Change from Baseline in 24-hour Ambulatory Diastolic Blood Pressure at Month 6 (ABPM)
Tidsramme: Baseline to Month 6 post-procedure
|
24-hour mean systolic BP measured by validated ambulatory BP monitoring |
Baseline to Month 6 post-procedure
|
|
Change from Baseline in Office Blood Pressure (including both systolic and diastolic BP)
Tidsramme: Baseline to Months 1, 3, 6 and 12 post-procedure
|
measured by validated office blood pressure monitoring |
Baseline to Months 1, 3, 6 and 12 post-procedure
|
|
Change from Baseline in 24-hour Ambulatory Systolic Blood Pressure (including both systolic and diastolic BP)
Tidsramme: Baseline to Months 1, 3, and 12 post-procedure
|
24-hour mean systolic BP measured by validated ambulatory BP monitoring |
Baseline to Months 1, 3, and 12 post-procedure
|
|
Change from Baseline in Daytime and Nighttime Ambulatory Systolic Blood Pressure (ABPM)
Tidsramme: Baseline to Months 1, 3, 6, and 12 post-procedure
|
24-hour mean systolic BP measured in Daytime and Nighttime by validated ambulatory BP monitoring |
Baseline to Months 1, 3, 6, and 12 post-procedure
|
|
Percentage of Participants with 24-hour Ambulatory Systolic BP <130 mmHg
Tidsramme: Months 1, 3, 6, and 12 post-procedure
|
24-hour mean systolic BP measured by validated ambulatory BP monitoring |
Months 1, 3, 6, and 12 post-procedure
|
|
Percentage of subjects with office systolic BP within the target ranges (<140 mmHg and <130 mmHg)
Tidsramme: Months 6 and 12 post-procedure
|
measured by validated office blood pressure monitoring |
Months 6 and 12 post-procedure
|
|
Responder Rate: ≥5 mmHg Reduction in office Systolic BP
Tidsramme: Months 6 and 12 post-procedure
|
Proportion of participants with a reduction ≥5 mmHg from baseline in office BP |
Months 6 and 12 post-procedure
|
|
Change from Baseline in Antihypertensive Medication Use
Tidsramme: Months 1, 3, 6 and 12 post-procedure
|
Change in the number of concurrently prescribed antihypertensive agents |
Months 1, 3, 6 and 12 post-procedure
|
|
Change from Baseline in serum creatinine levels
Tidsramme: Months 1, 3, 6 and 12 post-procedure
|
Change in postoperative serum creatinine levels relative to baseline |
Months 1, 3, 6 and 12 post-procedure
|
|
Changes from Baseline in glomerular filtration rate
Tidsramme: Months 1, 3, 6 and 12 post-procedure
|
Changes in glomerular filtration rate relative to baseline |
Months 1, 3, 6 and 12 post-procedure
|
|
Changes from Baseline in the urine microalbumin-to-creatinine ratio
Tidsramme: Months 1, 3, 6 and 12 post-procedure
|
Changes in the urine microalbumin-to-creatinine ratio relative to baseline |
Months 1, 3, 6 and 12 post-procedure
|
|
Change from Baseline in Heart Rate (by ECG)
Tidsramme: Months 1, 3, 6 and 12 post-procedure
|
Resting heart rate measured by standard 12-lead ECG; change is Follow-up minus Baseline |
Months 1, 3, 6 and 12 post-procedure
|
|
Change from Baseline in left ventricular ejection fraction (LVEF) (by Echocardiography)
Tidsramme: Months 12 post-procedure
|
by Echocardiography |
Months 12 post-procedure
|
|
Change from Baseline in left ventricular mass index
Tidsramme: Months 12 post-procedure
|
by Echocardiography |
Months 12 post-procedure
|
Samarbejdspartnere og efterforskere
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Urogenitale sygdomme
- Karsygdomme
- Hjerte-kar-sygdomme
- Patologiske processer
- Mandlige urogenitale sygdomme
- Nyresygdomme
- Urologiske sygdomme
- Urogenitale sygdomme hos kvinder
- Kvinders urogenitale sygdomme og graviditetskomplikationer
- Kronisk sygdom
- Sygdomsegenskaber
- Nyreinsufficiens
- Patologiske tilstande, tegn og symptomer
- Forhøjet blodtryk
- Nyreinsufficiens, kronisk
Andre undersøgelses-id-numre
- BRWEP2024W012060105
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .